Bratha

Part 4.0 — Protection

15 min read

This is Part 4 of 5 in the Performance Enhancement Series — the "Tier 3" continuation of the Fitness Series' Pharmacology chapter. The full path:

Table of Contents

Framing

This is the most important article in the series, because it’s the one that decides whether you stay in the game or get forced out of it. It is harm reduction, not medical advice. Many of the protective agents named here — ARBs, beta-blockers, statins, ezetimibe, SGLT2 inhibitors, PDE5 inhibitors, aspirin, cabergoline, SERMs, finasteride, anticoagulants — are prescription (or pharmacologically active OTC) medications with their own serious risks and interactions. None should be used without a physician. The mechanisms below are explained so you can have an informed conversation with a doctor, not so you can self-prescribe.

What “protection” actually means

Part 1 established the rule that defines this entire series: you have one set of organs and roughly 100,000 hair follicles, and the two things that force men to stop are almost always a health crisis or going bald. Your career as an enhanced athlete is finite by default.

Protection is the art of extending that career. Every strategy in this article does one of two things: it slows the rate at which you spend your finite resources, or it catches damage early enough to reverse it. This is also why the moderate, multi-pathway approach from Part 3 and the monitoring from Part 2 aren’t separate from protection — they are protection. Lower doses spread across more levers, watched closely, is the single biggest protective decision you make. Everything below is what you layer on top.

Cardiovascular: the thing most likely to kill you

Of every risk in this series, cardiovascular disease is the most likely to actually end you — Derek’s whole argument hinges on it, and the blood chemistry panel is built around catching it.[^1] It has four fronts. But before the four fronts and their defenses, it’s worth understanding what is actually happening inside the artery — because the interventions later only make sense once you see the mechanism.

How the damage actually happens

The lipid mechanism — why HDL craters. Anabolic steroids, and oral 17-alpha-alkylated compounds especially, strongly upregulate an enzyme in the liver called hepatic lipase.[^6] Hepatic lipase hydrolyses the phospholipids and triglycerides inside HDL particles — particularly the large, cardioprotective HDL2 fraction — which accelerates HDL breakdown and is why HDL can crash into single digits within weeks on a harsh oral. The same enzyme works on VLDL and IDL remnants, shifting them toward small, dense LDL — the most atherogenic particle there is. So you get the worst of both: HDL gutted, LDL and ApoB up, and the LDL that remains is the dangerous kind. Crashed estradiol (over-zealous AI use) makes it worse, because estrogen normally supports HDL.

From a blood number to a heart attack. Here is the chain that kills lifters who “looked healthy.” Excess ApoB-carrying LDL particles penetrate the artery wall, oxidise, and get engulfed by macrophages, which become cholesterol-laden foam cells → a fatty streak → a fibrous plaque.[^7] Meanwhile the gutted HDL can no longer run reverse cholesterol transport (ferrying cholesterol back to the liver), so plaque builds faster than it clears. Over years, a plaque can rupture; the body clots over the rupture; the clot occludes a coronary artery; the heart muscle downstream dies. That's a myocardial infarction — and it's why visibly shredded bodybuilders with abs you could grate cheese on drop dead at 35 or 45. The abs are irrelevant to a coronary artery; years of single-digit HDL, high ApoB, high blood pressure, an enlarged heart, and thick blood are not.

The blood-pressure mechanism — why the water shows up. Androgens raise blood pressure mainly by driving sodium and water retention: they activate the mineralocorticoid receptor (an aldosterone-like effect) and stimulate the renin-angiotensin-aldosterone system (RAAS), while aromatization to estrogen adds further fluid retention. Blood volume rises. Layer on erythrocytosis (rising hematocrit thickening the blood, below) plus reduced nitric-oxide vasodilation and higher sympathetic tone, and peripheral resistance climbs too. More volume pushing through stiffer, narrower, more resistant pipes = higher pressure — which then accelerates both plaque damage and cardiac remodeling. The three fronts aren't separate problems; they compound into one accelerated-atherosclerosis loop.

Lipids

Androgens shift your lipid profile the wrong way: HDL drops, LDL and ApoB climb. Oral 17-alpha-alkylated compounds (Dianabol, Anadrol, Winstrol, Halotestin) do this hardest and fastest — they can flatten HDL within weeks. Crashed estradiol makes it worse, which is one more reason not to abuse AIs (see Pathway 3).

Defense:

  • Minimize orals — duration and dose. They are the worst offenders for the smallest muscle-retention benefit.
  • Don’t crash estradiol — estrogen is lipid-protective; manage it with injection frequency, not AIs.
  • High-dose omega-3 (EPA/DHA) and citrus bergamot are the two most commonly used lipid-support supplements; both have reasonable evidence for nudging the panel back.[^5]
  • Keep saturated fat moderate during harsh cycles, and keep doing cardio — the “boring” base does real work here.
  • Watch HDL and ApoB on your mid-cycle bloods; if HDL is heading toward single digits, that’s a signal to change the protocol, not to push through.

Blood pressure

Androgens raise blood pressure through water and sodium retention and rising red-cell mass. Chronically elevated BP silently damages your heart, kidneys, eyes, and vasculature — and it’s invisible without measurement.

Defense:

  • Measure at home, constantly (the Part 2 cuff). Target generally <130/80; a trend upward is your earliest, cheapest warning.
  • Telmisartan (an angiotensin-receptor blocker) is a common harm-reduction choice because it controls BP and has a PPAR-modulating bonus; nebivolol is a beta-blocker option. Both are prescription drugs — physician territory.
  • Lifestyle levers still matter: sodium/potassium balance, hydration, cardio, sleep, and managing the hematocrit below.

Hematocrit and blood viscosity

This is the one people underestimate. Androgens stimulate red blood cell production, and a hematocrit that climbs too high thickens the blood, raising the risk of clots, stroke, and cardiac strain. The why, in two steps: androgens signal the kidneys to release more erythropoietin (EPO) — the hormone that tells bone marrow to manufacture red cells — and they suppress hepcidin, the iron-regulating hormone, which frees up more iron for that production. More EPO plus more available iron = climbing hematocrit. Boldenone/EQ is the standout driver (disproportionately erythropoietic for its dose), which is exactly why an EQ-containing stack earns the closest CBC watch.

Defense:

  • Track hematocrit/hemoglobin on the CBC. As it approaches roughly 52–54%, the standard response is therapeutic phlebotomy — donating blood — which is fast, free, and effective.[^2]
  • Hydrate well, especially around training and the draw itself.
  • Some users add low-dose aspirin or nattokinase for viscosity, but anticoagulants raise bleeding risk and interact with other meds — this is a physician decision, not a default.

The heart muscle itself

Over years, supraphysiological androgens are associated with left ventricular hypertrophy (the fibrotic, maladaptive kind) and impaired relaxation of the heart.[^1] Two mechanisms drive it, and the distinction matters for how you defend. The first is pressure — the heart wall thickens to pump thick blood against high resistance, so blood-pressure control addresses this half. The second is direct: cardiac muscle is dense with androgen receptors, so steroids signal heart cells to grow directly, independent of blood pressure. That’s why an ARB blunts the pressure half but dose, duration, and compound choice are the only levers on the direct half — no ancillary “fixes” AR-driven cardiac growth. You can’t supplement your way out of this — the defense is structural:

  • Limit cycle length and dose, and take real time at cruise/off.
  • Control blood pressure (above), which drives a lot of the remodeling.
  • Keep zone-2 cardio in the program year-round for a healthier heart.
  • For longer-term users, an echocardiogram and ECG belong on the periodic checklist alongside bloods.

Liver

Injectable testosterone is comparatively liver-friendly. The hepatic risk is concentrated in oral 17-alpha-alkylated steroids.

Defense:

  • Limit oral duration (the contest-prep-only discipline from Part 3 applies).
  • TUDCA is the most-used on-cycle liver-support supplement; NAC supports glutathione and broader detox capacity.
  • No alcohol stacked on top of oral steroids.
  • Read GGT, not just AST/ALT — as Part 2 explained, AST/ALT are inflated by training and creatine, so GGT and bilirubin are the cleaner liver signals.

Kidneys

The kidneys take collateral damage mostly from high blood pressure, very high lean body mass, dehydration, and certain harsh compounds — but a thick-blood stack adds a mechanism of its own. ==The hyper-viscous, high-hematocrit blood from Boldenone grinds mechanically through the delicate glomerular filters==, and that shear stress, on top of high filtration pressure, can scar the nephrons (focal segmental glomerulosclerosis). It’s the same hematocrit problem from above, cashing out as renal damage. The defenses overlap with cardiovascular protection:

  • Control blood pressure — the single biggest renal protector.
  • Stay hydrated; don’t run chronic dehydration for “dryness.”
  • Track kidney function with cystatin-C / eGFR (creatinine over-reads in muscular athletes — Part 2).
  • Be cautious stacking NSAIDs, high-dose creatine, and harsh compounds with already-high BP.

Estrogen and prolactin management

Part 3 made the case that estrogen is anabolic and protective and should be managed, not crushed. That’s the offensive framing; here’s the defensive one.

  • Estradiol: Control it primarily through injection frequency (smaller, more frequent doses smooth aromatization). Reserve aromatase inhibitors for genuine need, at the lowest effective dose, because crashed E2 brings joint pain, low libido, poor mood, brittle lipids, and weaker gains. Track E2 on mid-cycle bloods.
  • Gynecomastia: If estrogen-driven breast tissue starts developing, SERMs like raloxifene or tamoxifen are the evidence-based response (raloxifene is often favored for existing gyno). Acting early matters — established glandular tissue may only be removable surgically.
  • Prolactin: This is the one that misbehaves on 19-nors (Pathway 4). Mild support includes P5P (vitamin B6) and vitamin E; for significant elevation, cabergoline is effective but is a potent dopamine agonist with real side effects (and rare valvular concerns at high chronic doses) — physician-only, and a strong argument for just not running heavy 19-nors in the first place.

Fertility and the HPTA: HCG, PCT, and the TRT question

Part 1 said this is probably a lifetime commitment, and Part 2 had you bank a fertility baseline. Here’s how the suppression is actually managed.

On cycle — protecting the testes:

  • HCG mimics LH and keeps the testes active during suppression, preserving testicular size and intratesticular testosterone (which matters for fertility and makes recovery easier). It also feeds the progesterone pathway usefully.
  • HMG / FSH can be added when fertility preservation is a specific priority.

Coming off — Post-Cycle Therapy (PCT):

  • The classic PCT uses SERMs (tamoxifen, clomiphene) — sometimes with HCG beforehand — to restart the HPTA by prompting the pituitary to release LH and FSH again. The goal is to recover endogenous production rather than crash into a hormonal hole.

The honest fork in the road:

PCT vs. blast-and-cruise vs. TRT-for-life

There are really two long-term models. Cycle and recover (run a cycle, PCT, return to natural) preserves the most optionality but means repeatedly suppressing and restarting your axis. Blast-and-cruise (never fully come off — cruise on a TRT dose between blasts) is easier on the body in some ways but typically means lifelong hormone dependence. Derek’s own arc is the cautionary tale: years of high-dose cycles, then settling onto 100 mg/week of testosterone for life.[^3] ==Decide which model you’re choosing before you start — it’s the Part 1 commitment question made concrete.==

Hair: the other finite resource

For a huge number of men this — not health — is what actually forces them to stop, and it’s why Derek frames follicles as a finite resource right alongside organs.[^3] Male pattern hair loss is driven by DHT acting on genetically susceptible follicles. Androgens accelerate it; if you’re predisposed, cycles can take you from “thinning” to “severely balding” in your 20s or 30s, permanently.

The defensive toolbox (effectiveness and side effects both vary a lot by person):

  • 5-alpha-reductase inhibitors (finasteride, dutasteride) reduce the conversion of testosterone to DHT.[^4] Real caveats: a minority of users report persistent sexual or mood side effects, and ==they don’t help against steroids that are already DHT-derivatives== (e.g., Masteron, Winstrol, Anavar) — those bypass the enzyme entirely.
  • Topical finasteride aims for scalp effect with less systemic exposure — a common compromise.
  • Topical minoxidil (growth stimulation), ketoconazole shampoo (Nizoral) (anti-androgen at the scalp, anti-inflammatory), and microneedling are the standard adjuncts.
  • RU58841 is a topical anti-androgen popular in enhanced circles but is a research chemical with no long-term human safety data — flagged for transparency, not endorsement.

Compound selection is your first hair defense

If hair matters to you, the biggest lever isn’t a drug you add — it’s the compounds you don’t run. DHT-derivatives and high androgenic load are hardest on follicles. This is, again, the moderate approach paying off.

The rest: sleep, mind, skin, glucose

  • Sleep apnea. Gaining substantial mass (neck and tissue) raises sleep-apnea risk, which feeds back into blood pressure and cardiovascular strain. If you snore heavily or wake unrefreshed, get assessed.
  • Mental health and aggression. Supraphysiological androgens can affect mood, irritability, and aggression; some compounds (trenbolone especially) are notorious for it. Watch it honestly, and treat a bad reaction as a reason to change the protocol. Part 1 also flagged the psychological trap of being unable to stop — take that seriously.
  • Acne and skin. Androgen-driven; managed with the usual dermatological tools, and improved by keeping DHT and estrogen sane.
  • Glucose. GH and insulin (Pathways 7 & 8) impair insulin sensitivity — keep fasting glucose and HbA1c on the monitoring list whenever they’re in play.

Super Ancillaries: drugs that pull double duty

The foundational moves come first, always: lower dose, fewer orals, manage estrogen instead of crushing it, cardio, sleep, and relentless monitoring. But when a marker won’t come back into range on lifestyle and supplements alone — or when an athlete is going to run regardless — there’s a tier of pharmacological defense. ==The best of these are “super ancillaries”: single drugs that pull double or triple duty, defending more than one front at once.== Grouped by mechanism:

Lipid defense — close the cholesterol doors. This is the direct counter to the hepatic-lipase dyslipidemia above.

  • Statins (HMG-CoA reductase inhibitors — e.g., rosuvastatin, atorvastatin). They block the rate-limiting enzyme of hepatic cholesterol synthesis (the mevalonate pathway). With less cholesterol made internally, the liver upregulates LDL receptors and pulls LDL out of the bloodstream — LDL and ApoB drop.[^8] This is the mainstay when AAS-driven LDL won’t yield to diet, omega-3, and cutting orals.
  • Ezetimibe (an NPC1L1 inhibitor). Closes the other door: it blocks cholesterol absorption at the small-intestine brush border. It lowers LDL on its own and is strongly synergistic stacked with a statin — two sources of cholesterol shut off at once, often with better tolerance than simply escalating the statin.[^9]
  • PCSK9 inhibitors (evolocumab, alirocumab) — the heavy artillery: injectable antibodies that prevent LDL-receptor degradation for large LDL reductions, reserved for refractory cases.

Glucose defense — for GH/insulin-driven insulin resistance (Pathways 7 & 8):

  • SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin). They block glucose reabsorption in the kidney’s proximal tubule, so excess glucose is excreted in the urine. They lower blood glucose and blood pressure and body weight, with proven cardio-renal protection — a genuine super ancillary for the GH-using athlete.[^10] Caveats are real: euglycemic ketoacidosis, genital fungal infections, and dehydration. (Berberine/metformin are the gentler first rung from Part 3.0.)

Blood-flow and pressure defense:

  • PDE5 inhibitors — Tadalafil is the multi-effect champion. Daily low-dose tadalafil vasodilates, which lowers blood pressure, improves blood flow and training pumps, supports erectile function and endothelial health, and eases BPH symptoms. One drug, several protective jobs — the prototype “super ancillary,” and its long half-life makes it the daily-use PDE5 of choice.[^11]
  • Telmisartan (your BP ARB) is itself double-duty — a partial PPAR-γ agonist that also nudges insulin sensitivity and lipids. Nebivolol is a beta-blocker that a

Graph View

Backlinks